Narayana Hrudayalaya Ltd. (NH) AI Stock Analysis

• Market Cap: ₹358.95B
• Dividend Yield: 0.26%
• Average Volume (3M): 25.86K
• Price to Earnings (P/E): 45.5
• Beta (1Y): 0.70
• Revenue Growth: 12.09%
• EPS Growth: -2.79%
• Country: IN
• Employees: 11,659
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 9.60
• Shares Outstanding: 204,360,800
• 10 Day Avg. Volume: 19,760
• 30 Day Avg. Volume: 25,862
• PEG Ratio: 0.00
• Price to Book (P/B): 9.40
• Price to Sales (P/S): 6.22
• P/FCF Ratio: -354.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,743.33
• Price Target Upside: -0.75% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3

• Rating: 67 Neutral
• Price Target: ₹1,915.00 ▲(9.03% Upside)

Narayana Hrudayalaya Ltd. has a solid financial foundation with strong revenue growth and profitability, which is the most significant factor in its score. Technical analysis presents a mixed outlook with some bearish signals. The stock appears overvalued based on its high P/E ratio, which impacts its overall attractiveness.

Narayana Hrudayalaya Ltd. Business Overview & Revenue Model

Company Description

Narayana Hrudayalaya Limited provides medical and healthcare services. The company operates and maintains hospitals, clinics, health centers, nursing homes, and other related activities. It offers services in various specialties, including cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicines, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology. As of June 30, 2022, the company operated through a network of 19 owned/operated hospitals, 2 managed hospitals, 4 heart centers, and 18 clinics and information centers in India, as well as a hospital in the Cayman Islands. It also provides healthcare consultancy services, including licensing of ERP solutions. The company was incorporated in 2000 and is headquartered in Bengaluru, India.

How the Company Makes Money

Narayana Hrudayalaya Ltd. generates revenue primarily through its network of hospitals and healthcare facilities. The company's key revenue streams include patient fees for medical services, surgeries, and diagnostic services. NH also earns from outpatient consultations and pharmacy sales within its facilities. Additionally, its strategic partnerships with government bodies and health insurance companies contribute to its earnings by ensuring a steady flow of patients and facilitating payment processes. The company may also derive income from international patients seeking specialized medical treatments, and it focuses on cost-efficient operations to maintain profitability.

Narayana Hrudayalaya Ltd. Financial Statement Overview

Summary

Narayana Hrudayalaya Ltd. demonstrates strong financial health with robust revenue growth and profitability. The balance sheet reflects prudent financial management, although increasing debt levels need monitoring. Cash flow management is generally effective, despite the recent dip in free cash flow.

Income Statement

Narayana Hrudayalaya Ltd. has shown a strong financial performance with consistent revenue growth, increasing from 25.8 billion in 2021 to 54.8 billion in 2025. The gross profit margin has improved, indicating better cost management. The net profit margin has remained stable, demonstrating profitability. However, the decline in EBITDA margin from 2024 to 2025 suggests potential cost pressures or investment in growth.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity position. The debt-to-equity ratio is manageable, indicating prudent financial leverage. An increasing equity ratio suggests effective asset management. However, the rising total debt from 2022 to 2025 could pose future financial risks if not managed carefully.

Cash Flow

The cash flow position is relatively stable, with positive operating cash flow consistently over the years. Despite a dip in free cash flow in 2025 due to higher capital expenditure, the overall cash flow management remains robust. The operating cash flow to net income ratio indicates efficient conversion of income into cash, although the negative free cash flow in 2025 warrants attention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	57.49B	54.83B	48.90B	45.30B	37.01B	25.84B
Gross Profit	24.69B	21.12B	18.41B	16.76B	12.13B	6.42B
EBITDA	12.59B	12.28B	11.02B	9.31B	6.19B	1.43B
Net Income	7.85B	7.90B	7.89B	6.06B	3.42B	-143.04M
Balance Sheet
Total Assets	0.00	72.65B	56.25B	41.62B	31.30B	27.70B
Cash, Cash Equivalents and Short-Term Investments	16.27B	16.27B	11.04B	6.51B	3.01B	2.39B
Total Debt	0.00	24.28B	16.27B	8.84B	7.23B	8.26B
Total Liabilities	-36.28B	36.37B	27.39B	20.30B	16.40B	16.49B
Stockholders Equity	36.28B	36.26B	28.84B	21.31B	14.89B	11.20B
Cash Flow
Free Cash Flow	0.00	-961.81M	959.93M	5.63B	2.34B	2.39B
Operating Cash Flow	0.00	9.86B	10.67B	10.85B	4.85B	3.09B
Investing Cash Flow	0.00	-13.25B	-14.58B	-11.74B	-2.67B	-1.13B
Financing Cash Flow	0.00	5.44B	4.88B	877.41M	-1.59B	-1.98B

Narayana Hrudayalaya Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1756.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NH, the sentiment is Neutral. The current price of 1756.45 is above the 20-day moving average (MA) of 1753.56, below the 50-day MA of 1776.90, and above the 200-day MA of 1696.86, indicating a neutral trend. The MACD of -7.08 indicates Negative momentum. The RSI at 47.45 is Neutral, neither overbought nor oversold. The STOCH value of 21.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NH.

Narayana Hrudayalaya Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	₹642.22B	18.94	―	0.36%	7.76%	-2.84%
FORTIS	75 Outperform	₹819.24B	94.33	―	0.09%	14.04%	32.99%
MEDANTA	71 Outperform	₹374.96B	70.14	―	0.04%	15.42%	10.66%
NH	67 Neutral	₹358.95B	45.49	―	0.26%	12.09%	-2.79%
KIMS	65 Neutral	₹293.62B	76.52	―	―	24.71%	19.17%
HCG	61 Neutral	₹99.96B	275.51	―	―	16.85%	-29.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Narayana Hrudayalaya Ltd. Corporate Events

Narayana Hrudayalaya Releases Revised Q1 FY26 Investor Presentation

Narayana Hrudayalaya Ltd. has submitted a revised Investor Presentation for the quarter ending June 30, 2025, to the stock exchanges. This update is part of the company’s ongoing efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.

Narayana Hrudayalaya Receives Regulatory Nod for Scheme of Arrangement

Narayana Hrudayalaya Ltd. has announced the receipt of observation letters from both BSE Limited and the National Stock Exchange of India, indicating ‘no adverse observations’ and ‘no objection’ respectively, for its proposed Scheme of Arrangement with its subsidiary, Meridian Medical Research & Hospital Ltd. This development marks a step forward in the amalgamation process, although the scheme still requires further statutory and regulatory approvals, including from the National Company Law Tribunal and the company’s shareholders and creditors.